24-Hour Test to Determine Effectiveness of Breast Cancer Treatment
Wednesday, September 1st, 2010Anthracycline, the most commonly used chemotherapy drug for breast cancer patients in the UK, is only effective in about one-fourth of the 46,000 women who are diagnosed with breast cancer each year in the UK.
A new test developed at the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research (ICR) in London would help the other three-fourths of breast cancer patients avoid needless chemotherapy with the stress and side effects that accompany it.
The test may also predict whether ovarian cancer patients will respond to chemotherapy and could be adapted for other forms of the disease.
Usually breast cancer patients find out after a three-month course of treatment they are not benefiting from Anthracycline.
With the new test, they can find out in 24 hours and move on to more effective treatment options.
I hope the new 24-hour test to determine the effectiveness of breast cancer treatment with Anthracycline will soon be standard procedure all over the world and will also be able to determine the effectiveness of other types of chemotherapy.



